Latest Breaking News On - Kiora - Page 9 : comparemela.com

Putting Australian clinical research on the map globally, comes the ground-breaking first-in-human clinical trial for KIO-301. MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ In collaboration with US-based Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and The Royal Adelaide Hospital, leading Australian CRO, Accelagen, is proud to announce that dosing has commenced in the Phase 1 first-in-human trial for KIO-301. This trial represents a remarkable development in the treatment of people with the rare inherited condition, Retinitis Pigmentosa (RP), which currently has no approved cure or standard treatment. Always at the forefront of full service pharmaceutical and medical device development worldwide, Accelagen's work is first and foremost about accelerating and improving the future of human health: "Clinical research is not about just testing something in a group of trial participants. It is about creating measurable improvements for people's health and wellbeing that will

South australiaNew south walesGreg plunkettBrianm stremNicole kanellopoulos remyRobert cassonKiora pharmaceuticalsKiora pharmaceuticals incContract research organisationPutting australianRoyal adelaide hospitalRetinitis pigmentosaRoyal adelaideProfessor robert cassonChief executive officerRemy arena